Consistent Cardiovascular (CV) Benefit of Empagliflozin Over the Spectrum of CV Risk Factor Control in EMPA-REG OUTCOME
Metabolism: Clinical and Experimental- Netherlands
doi 10.1016/j.metabol.2019.12.071
Full Text
Abstract
Available in
Date
March 1, 2020
Authors
Publisher
Elsevier BV